The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N02 | Analgesics | |
| 3 | N02C | Antimigraine preparations | |
| 4 | N02CA | Ergot alkaloids | |
| 5 | N02CA01 | Dihydroergotamine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| NASAL - Nasal | 1 mg |
| ORAL - Oral | 4 mg |
| PAREN - Parenteral | 4 mg |
| Active Ingredient | Description | |
|---|---|---|
| Dihydroergotamine |
Dihydroergotamine binds with high affinity to 5-HT1DĪ± and 5-HT1DĪ² receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors. The therapeutic activity of dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| MIGRANAL Nasal spray | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
